The core value driver remains KT-621, Kymera’s STAT6-targeting program. “STAT6 remains [the] primary driver to the story,” ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Labcorp (LH), and Gilead (GILD) rise as Supreme Court upholds right to free preventive care under Obamacare. Read more here.

The rapid adoption of the Omnipod 5 answered a question automated insulin delivery system manufacturers posed for years: with ...

Cineplex Inc . (TSX:CGX) stock rose 5% Friday after the company announced that longtime President and CEO Ellis Jacob will retire on December 31, 2026.

Boeing is entering a new phase of recovery that could support a market reassessment of its stock, according to analysts at Redburn.

Guggenheim raised its price target on Walt Disney (NYSE:DIS) Co to $140 from $120 on stronger-than-expected trends across sports advertising, theme parks, and progress on cost-cutting as the company ...

Gilead and Arcus entered into a $2 billion alliance in 2021 in which Gilead exercised options on four drug candidates, including domvanalimab, follow-up TIGIT AB308, adenosine A2a/A2b receptor ...

Kymera signs $750m cancer deal with Gilead as Sanofi opts in. Kymera is celebrating the signing of two partnerships, with Gilead taking an option on one molecular glue programme, as Sanofi buys ...